Jounce Therapeutics Inc. (JNCE)
NASDAQ: JNCE
· Real-Time Price · USD
1.88
0.00 (0.00%)
At close: May 03, 2023, 10:00 PM
Jounce Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 150.57M | 77.11M | 77.74M | 60.41M | 95.53M | 145.37M | 140.81M | 196.27M |
Short-Term Investments | 38.97M | 51.5M | 70.82M | 95.01M | 83.04M | 74.23M | 79.32M | 61.2M |
Long-Term Investments | n/a | 1.72M | 13.69M | 30.98M | 41.66M | 29.44M | 26.02M | 13.81M |
Other Long-Term Assets | 3M | 3.06M | 3.19M | 3.33M | 3.45M | 3.58M | 3.6M | 3.48M |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | 24.98M | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 7.69M | 11.32M | 8.78M | 9.42M | 12.26M | 9.64M | 12.01M | 9.54M |
Total Current Assets | 197.23M | 139.93M | 157.35M | 164.84M | 190.83M | 229.25M | 257.12M | 267.01M |
Property-Plant & Equipment | 12.32M | 13.37M | 14.68M | 15.53M | 16.76M | 18.12M | 19.43M | 20.86M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 15.32M | 18.15M | 31.55M | 49.84M | 61.87M | 51.14M | 49.04M | 38.14M |
Total Assets | 212.55M | 158.08M | 188.9M | 214.67M | 252.7M | 280.38M | 306.16M | 305.15M |
Account Payables | 2.1M | 1.11M | 3.44M | 1.9M | 1.67M | 1.75M | 2.48M | 1.63M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 392K |
Short-Term Debt | 4.15M | 4.02M | 3.91M | 3.8M | 7.39M | 3.58M | 3.48M | 3.38M |
Other Current Liabilities | 17.32M | 16.66M | 15.84M | 11M | 9.83M | 12.76M | 9.89M | 7.52M |
Total Current Liabilities | 23.57M | 21.8M | 23.2M | 16.7M | 18.9M | 18.1M | 15.84M | 12.93M |
Long-Term Debt | 5.87M | 6.93M | 7.98M | 9.01M | 9.99M | 10.92M | 11.86M | 12.77M |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 5.87M | 6.93M | 7.98M | 9.01M | 9.99M | 10.92M | 11.86M | 12.77M |
Total Liabilities | 29.44M | 28.72M | 31.17M | 25.71M | 28.89M | 29.02M | 27.7M | 25.7M |
Total Debt | 10.02M | 10.95M | 11.89M | 12.81M | 17.38M | 14.5M | 15.34M | 16.15M |
Common Stock | 51K | 51K | 51K | 51K | 51K | 51K | 51K | 51K |
Retained Earnings | -292.79M | -343.75M | -312.75M | -279.24M | -241.87M | -211.64M | -181.55M | -177.54M |
Comprehensive Income | -677K | -1.03M | -1.1M | -901K | -238K | -19K | -24K | -25K |
Shareholders Equity | 183.11M | 129.36M | 157.73M | 188.96M | 223.81M | 251.37M | 278.46M | 279.45M |
Total Investments | 38.97M | 53.22M | 84.51M | 125.98M | 124.69M | 103.67M | 105.33M | 75.01M |